Is this you?
Request access for Urology Associates PC with your @urologynashville.com work email. Intera will contact you to verify and set up your account — nothing auto-publishes.
Urology Associates PC
Unclaimed profileSite Network · Nashville, Tennessee (and Denver, Colorado locations) · ~8 sites
Intera lens
ICP 7Lift (cardio sample) 0.47Recruit soph 0.14
Quality Scorecard (1–100)
Overall71Recruit46Ops79Sponsor79Ther87
Performance (observed)
Historical trials
379
Completed
179
Terminated/Withdrawn
37
Completion rate
83%
Active now
154
Phase 2
137
Phase 3
193
Realized enrollment
212,239
First study year
1998
Years active
27
Match confidence
high
Enrollment velocity (inf)
7,861
Therapeutic
Areas
Urology, Prostate Cancer, Bladder Cancer, Kidney Cancer, Erectile Dysfunction, Stress Urinary Incontinence
Specialties
Urology
Breadth (conditions)
1,076
States
Alabama, Colorado, Tennessee
Recruitment (web observed)
Advertises recruitment
Yes
Capability notes
Multi-state urology focus with Advanced Therapeutics Center for complex cases
Relationships
Sponsors
National Cancer Institute (NCI); Alliance for Clinical Trials in Oncology; SWOG Cancer Research Network; ECOG-ACRIN Cancer Research Group; Pfizer; Ferring Pharmaceuticals
CROs
Covance; ICON Clinical Research; PPD Development, LP; PRA Health Sciences; Parexel
Owner / parent
Physician-owned practice
Capacity & people
Investigators
—
Coordinators
—
CEO
David Morris, M.D. (President)
VP Clinical Ops
J. Matthew Hassan, M.D. (Chief Medical Officer)
VP Site Ops
Amber Glass (Director of Operations)
VP Recruitment
Gautam Jayram, M.D. (Co-director of Advanced Therapeutics Center)
Emails
kimberly.ulibarri@uradenver.com
Tech & DCT
eSource
Yes
Builds tech
Vendors
Tech stack
12-lead ECG, advanced diagnostic equipment, research coordination systems
Recruiting visible
Y
Notes
CTGOV Signal: 5 recruiting trials across 3 locations (Alabama, Colorado, Tennessee). Active in research division with groundbreaking clinical trials. Advanced Therapeutics Center for complex cancer treatments. Multi-state presence with research coordinators experienced in trial coordination. Strong urologic oncology focus.
Recommendation features (sample indication)
Ind fit 0.55Liftability 0.47Overall71
FUTURE MOAT: absolute enrollment rates, funnel CPR, measured SSU, screen-fail reasons.